TriGemX Bio to Combine with TCGX Acquisition Corp.

Cooley advised TriGemX Bio, a biotechnology company focused on developing elismetrep, a potential first-in-class treatment for migraine, on its definitive business combination agreement with TCGX Acquisition Corp. (Nasdaq: TCGX), a special purpose acquisition company (SPAC) sponsored by TCGX. Cooley Advised TriGemX Bio on Business Combination Agreement with TCGX Acquisition Corp.

Corxel Pharmaceuticals to Combine with Amanat Acquisition Corp

Cooley advised Corxel Pharmaceuticals, a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for obesity and related cardiometabolic conditions, on its definitive business combination agreement with Amanat Acquisition Corp., a publicly traded special purpose acquisition company. Cooley Advised Corxel Pharmaceuticals on Business Combination Agreement with Amanat Acquisition Corp

Prana Therapies to be Acquired by Bolt Biotherapeutics

Cooley advised Prana Therapies, a clinical-stage biotechnology company pioneering next-generation half-life-extended multispecific antibodies, on its agreement to be acquired by Bolt Biotherapeutics, a clinical-stage biotechnology company pioneering a new generation of half-life-extended multispecific antibodies. Cooley Advised Prana Therapies on Agreement to Be Acquired By Bolt Biotherapeutics

Blink Labs Joins Forces With Gattaca

Cooley advised Gattaca, a venture-backed blockchain infrastructure company based in London, on its acquisition of Blink Labs, a platform that helps wallets and applications route and protect their users’ transactions. Blink Labs Joins Forces With Gattaca

Goal Solutions Strategic Investment from Brown Brothers Harriman

Cooley advised Goal Solutions, a leading provider of loan servicing, asset management, SPV administration and analytics solutions, on its significant strategic minority equity investment from the private equity investment arm of Brown Brothers Harriman, a global financial services firm. Cooley Advised Goal Solutions on Strategic Investment from Brown Brothers Harriman

Rebel Girls Acquired by Her Campus Media

Cooley advised Rebel Girls, the trailblazing global, multi-platform media brand dedicated to helping raise the most inspired and confident generation of girls, on its acquisition by Her Campus Media, the leading media company dedicated to empowering, uplifting, and supporting college women. Cooley Advised Rebel Girls on Acquisition By Her Campus […]

Silence Therapeutics to be Acquired by Merck KGaA, Darmstadt, Germany for $1.3 Billion

Cooley advised London-headquartered, NASDAQ-listed Silence Therapeutics, a global clinical-stage biotechnology company developing precision engineered medicines using its proprietary siRNA technology, on its agreement to be acquired by leading science and technology company Merck KGaA, Darmstadt, Germany, in an all-cash transaction with an equity value of approximately $1.3 billion, subject to […]

Proscia to be Acquired by Agilent Technologies

Cooley advised Proscia, a provider of digital pathology software for clinical and life-sciences customers, on its agreement to be acquired by Agilent, a global leader in analytical and clinical laboratory technologies, for $240 million in all-cash at closing and up to an additional $30 million based on achieving future performance […]

Rocket Software Announces Acquisition of Geniez AI

Cooley advised Geniez AI, a generative AI company, on its acquisition by Rocket Software, a global technology leader in modernization software. Rocket Software Announces Acquisition of Geniez AI

Freshworks to Acquire Torii

Cooley advised Freshworks, the AI-powered, unified service operations platform that is fast to deploy, intuitive to use, and enables every employee to be more productive, on its agreement to acquire Torii, a software company helping teams turn hidden SaaS and AI activity into governed, accountable operations. Cooley Advised Freshworks on […]